Abstract: An imine compound represented by the formula: wherein A represents a heterocyclic group; R1, R2, an R3 each represent a hydrogen atom, a halogen atom, a C1-10 alkyl group optionally substituted with an aryl group(s) substituted with a halogen atom(s), a C3-10 cycloalkyl group, a C1-6 haloalkyl group, a C1-10 alkoxy group, etc.; R4 represents an optionally substituted C1-10 alkyl, C2-6 alkenyl, or aryl group; R5 represents a hydrogen atom, a C1-10 alkoxy group, a C1-6 haloalkyl group, an optionally substituted C1-10 alkyl or C2-6 alkenyl group, an optionally substituted aryl or heterocyclic group, etc.; W represents —CO—, —CO—CO—, —CO—NH—, —CS—NH—, or —SO2—, or a cannabinoid-receptor agonist comprising said imine compound as an active ingredient. The imine compound of the present invention has a cannabinoid-receptor agonist effect, and is useful as a therapeutic or prophylactic drug for pains and autoimmune diseases.

Abstract: Proteins comprising any of the amino acid sequences of SEQ ID NOS: 1 to 18 and DNAs encoding said proteins and comprising any of the nucelotide sequences of SEQ ID NOS: 19 to 36 are provided.

Abstract: A human membrane antigen TM4 superfamily protein existing on the osteosarcoma cell surface and a cDNA encoding this protein is provided, said protein being useful as a pharmaceutical for treatment and diagnosis of cancers and also as an antigen for preparation of an antibody against said protein.

Abstract: Cloning of human cDNAs coding for galectin-9-like proteins, expression with Escherichia coli of proteins encoded by these human cDNAs, and determination of the lactose-binding activity of these expression products.

Abstract: The invention provides human proteins having transmembrane domains and cDNAs coding for these proteins as well as eucaryotic cells expressing said cDNAs. All of the proteins exist in the cell membrane, so that they are considered to be proteins controlling the proliferation and the differentiation of the cells. Accordingly, the proteins can be employed as pharmaceuticals such as carcinostatic agents relating to the control of the proliferation and the differentiation of the cells or as antigens for preparing antibodies against said proteins. The cDNAs can be utilized as probes for the gene diagnosis and gene sources for the gene therapy. Furthermore, the cDNAs can be utilized for large-scale expression of said proteins. Cells, wherein these membrane protein genes are introduced and membrane proteins are expressed in large amounts, can be utilized for detection of the corresponding ligands, screening of novel low-molecular pharmaceuticals, and so on.

Abstract: The present invention provides a human PEC-60-like protein, a gastrointestinal hormone excreted by a stomach tissue and a cDNA encoding this protein. The protein and the gene of the present invention can provide a protein containing the amino acid sequence represented by Sequence No. 1 and a DNA encoding said protein exemplified as a cDNA containing the base sequence represented by Sequence No. 1 as well as a human cDNA encoding a human PEC-60-like protein and said protein by the expression of this human cDNA recombinant.

Abstract: Proteins containing any of the amino acid sequences represented by Sequence No. 1 to Sequence No. 2 or by Sequence No. 4 to Sequence No. 25 and DNAs encoding said proteins exemplified by cDNAs containing any of the base sequences represented by Sequence No. 26 to Sequence No. 50. Said proteins can be provided by expressing cDNAs encoding human proteins having transmembrane domains and recombinants of these human cDNAs.

Abstract: The invention provides cDNAs coding for human proteins having transmembrane domains and eucaryotic cells expressing said cDNAs. The cDNAs of the invention can be utilized as probes for the gene diagnosis and gene sources for the gene therapy. Furthermore, the cDNAs can be utilized for large-scale expression of said proteins. Cells, wherein these membrane protein genes are introduced and membrane proteins are expressed in large amounts, can be utilized for detection of the corresponding ligands, screening of novel low-molecular pharmaceuticals, and so on.

Abstract: A human membrane antigen TM4 superfamily protein existing on the osteosarcoma cell surface and a cDNA encoding this protein is provided, said protein being useful as a pharmaceutical for treatment and diagnosis of cancers and also as an antigen for preparation of an antibody against said protein.

Abstract: The present invention provides a human PEC-60-like protein, a gastrointestinal hormone excreted by a stomach tissue and a cDNA encoding this protein. The protein and the gene of the present invention can provide a protein containing the amino acid sequence represented by Sequence No. 1 and a t DNA encoding said protein exemplified as a cDNA containing the base sequence represented by Sequence No. 1. as well as a human cDNA encoding a human PEC-60-like protein and said protein by the expression of this human cDNA recombinant.

Abstract: The present invention provides a human PEC-60-like protein, a gastrointestinal hormone excreted by a stomach tissue and a cDNA encoding this protein. The protein and the gene of the present invention can provide a protein containing the amino acid sequence represented by Sequence No. 1 and a DNA encoding said protein exemplified as a cDNA containing the base sequence represented by Sequence No. 1. as well as a human cDNA encoding a human PEC-60-like protein and said protein by the expression of this human cDNA recombinant.

Abstract: Isolated cDNAs derived from mRNAs expressed in human cells are provided, as are DNAs and RNAs comprising their nucleotide sequences, and vectors for expressing the cDNAs. The cDNAs encode proteins which have functions similar to known proteins.

Abstract: Isolated cDNAs derived from mRNAs expressed in human cells are provided, as are DNAs and RNAs comprising their nucleotide sequences, and vectors for expressing the cDNAs. The cDNAs encode proteins which have functions similar to known proteins.

Abstract: A process for providing cDNAs containing full primary structure information of proteins by selectively synthesizing full-length cDNAs containing sequences starting from the capped region of mRNAs is disclosed. The invention provides a process for producing an intermediate for the synthesis of a full-length cDNA, which comprises the steps of treating mRNA extracted from cells to eliminate the phosphate group from the 5' end of an uncapped degraded mRNA; decapping from the 5' end of a capped intact mRNA; and ligating either a DNA oligonucleotide or a DNA-RNA chimeric oligonucleotide represented by the following general formula [I] to the 5' end phosphate group formed in the above step by the action of T4 RNA ligase, thereby selectively adding either the DNA oligonucleotide or the DNA-RNA chimeric oligonucleotide having an arbitrary sequence to the 5' end of the intact mRNA.5'-dN1-dN2- . . . -dNm-N1-N2- . . .